Open terminalDashboard

Last updated Nov 16, 8:18 AM ET · 1 update

Johnson & Johnson to acquire Ollin Biosciences for $2.2 billion upfront

J&J says it will buy eye-disease drug developer Ollin Biosciences for $2.2 billion upfront, plus possible milestone payments.

  1. Johnson & Johnson said on Monday, November 16, 2026 that it has signed a definitive agreement to acquire Ollin Biosciences, a clinical-stage biopharmaceutical company focused on serious eye diseases, for $2.2 billion upfront, according to the company's release carried by Business Wire.

What happened

Johnson & Johnson announced in a release distributed by Business Wire that it will acquire Ollin Biosciences, a clinical-stage biopharmaceutical company developing treatments for serious eye diseases. The company said the deal includes $2.2 billion paid upfront, with further regulatory and commercial milestone payments possible depending on outcomes. Business Wire's release noted the acquisition centers on a late-stage bispecific antibody, a lab-made protein that can bind two different targets at once, that Johnson & Johnson described as having best-in-class potential in ophthalmology, the branch of medicine focused on eye care.

How the stock has moved

Johnson & Johnson shares traded at $288.85 in pre-market trading, before the regular session opens, up 1.08% from Friday's close of $285.75. The move matches the stock's gain since the deal was first reported.

Johnson & Johnson (JNJ) since the news
MeasureValue
Price, pre-market trading$288.85
Since the close before the first report (Friday, November 13, 2026)+1.08%
Change from the close on Friday, November 13, 2026+1.08%
Market value at the close on Friday, November 13, 2026$687.89 billion

Source: Stock quote; the close before the first report from our saved closes · as of November 16, 2026 at 8:18 AM ET · Shows what the stock did after the news was first reported, not why.

Its suppliers and customers

Among suppliers and customers named in company filings, Microsoft and Martin Marietta Materials were trading higher outside the regular session, while Citigroup was lower. Intra-Cellular Therapies, Shockwave and Halda Therapeutics, also named in filings, showed no trades outside the regular session.

Suppliers and customers of Johnson & Johnson, and how they are trading
CompanyRoleStockSince last close
MicrosoftSupplierMSFT+0.16%
CitigroupSupplierC-0.62%
Martin Marietta MaterialsSupplierMLM+0.94%
Intra-Cellular TherapiesCustomerNot listed—
ShockwaveCustomerNot listed—
Intra-Cellular TherapiesSupplierNot listed—
Halda TherapeuticsSupplierNot listed—

Source: Relationships named in company filings (Earnings call transcript; SEC 10-K annual report); stock quotes · as of November 16, 2026 at 8:18 AM ET · A supplier or customer moving the same day is not evidence that one move caused the other.

Sources

  • — Business Wire

How this was made

Written from WiseView data and the sources credited above, and checked before it went up. It is updated as new reports come in, and every update is checked before it goes up. How this report is made

For information only, not investment advice.

More from the desk

Follow MLM, C and MSFT in the terminal.

Every panel, HootAI, the squawk and the pre-market board, on one membership.

Annual

$83/mo

Billed annually, $997 once a year.

Monthly

$127/mo

Billed monthly. Cancel any time.

14-day free trial · no card needed · nothing to cancel. Buying for a team? Seats on one invoice.